The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Identifying the Role of R-BAC Maintenance in MCL

Andre Goy, MD
Published Online:8:27 PM, Fri May 10, 2019


Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses the role of rituximab (Rituxan) and bendamustine plus cytarabine (R-BAC) as a treatment for patients with mantle cell lymphoma (MCL).

Goy says the data with R-BAC are interesting because the agents are combined to get the best of both rituximab and bendamustine, with low-dose cytarabine for age and myelotoxicity. Outside of clinical trials, Goy says R-BAC is an appealing option because it offers a sustainable progression-free survival, duration of response, and a very high complete response rate.

This has become the standard now as maintenance for patients with MCL. It has been shown to be beneficial in terms of duration of response and survival in both younger and elderly patients, Goy concludes.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.